Research article · 6 Oct 2026
Conference abstractPublished 24 Sep 2018
Apo-bovine lactoferrin nanoparticles supress hypoxia-angiogenesis pathway in macular degeneration model
Deakin University, Australia
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Aged macular degeneration (AMD) is the main cause of permanent vision loss in elderly1. The major challenge in the management of AMD is the development of the non-invasive therapy that able to cross the ocular barriers and reach to the posterior segment of the eye to exert the therapeutic efficacy. An iron-free form of bovine lactoferrin (Apo-bLf) has anti-angiogenic and anti-inflammatory activity. We assessed the protective role of Apo-bLf ultrasmall chitosan nanoparticles (Apo-bLf US-CHNP) as an anti-angiogenic agent and to suppress the hypoxia - angiogenesis pathway. Characterisation of the synthesized nanoparticles indicated that their size was around 14 nm, spheroid shape detected by Dynamic Light Scattering (DLS) and Transmission Electron Microscopy (TEM). While Fourier Transforms Infrared Spectroscopy (FTIR) showed the presence of Apo-bLf protein and chitosan within prepared nanoparticles. Differential scanning calorimetry was used to determine the thermal stability and water holding capacity of the prepared nanoparticles. Encapsulation efficacy was more than 91%. Continuous protein release for Apo-bLf nanoparticles was displayed an initial release in PBS (pH 7.2 and 7.6) at 37 C during the first 24 h and then exhibited zero-order drug release kinetics up to 96h (detection time at the 2h interval). Apo-bLf US-CHNP downregulated effectively the common AMD biomarkers such as VEGF, HIF 1-α, Cas-3, Bax, MMP9 and augment α-Crystallin in vitro for RPE-19 when exposed to oxidative stress; moreover, they suppress angiogenesis (screening expression of 55 key angiogenic markers) within AMD models in vitro and ex vivo. Therefore ApobLf US-CHNP may hold the promise for the prolonged therapeutic management of retinal degenerative diseases since they possess anti-apoptosis, anti-oxidant and anti-inflammatory effects.
Subjects
Ophthalmology & OptometryAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Clinical and Experimental Ophthalmology.
Short communication · 30 Aug 2026
Vision Science in the Modern Era: Integrating Neuroscience, Genetics, and Technology
Commentary · 3 Aug 2026
Emerging Frontiers in Experimental Ophthalmology: Innovations and Translational Challenges
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical and Experimental Ophthalmology
- SubjectOphthalmology & Optometry
- BylineArticles whose byline prints “Afrah Jalil Abd”
- BylineArticles whose byline prints “Rupinder Kaur Kanwar”
- BylineArticles whose byline prints “Kislay Roy”
- BylineArticles whose byline prints “Jagat Rakesh Kanwar”
